Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

  • Post author:
  • Post published:June 1, 2026
  • Post category:

Continue ReadingGene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingAutologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingCD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingExpanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingThe American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingStudy of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingExpanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
  • 1
  • 2
  • 3
  • 4
  • …
  • 14
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us